Successful Prospective Prediction of Type 1 Diabetes in Schoolchildren Through Multiple Defined Autoantibodies: an 8-year Follow-up of the Washington State Diabetes Prediction Study
Overview
Authors
Affiliations
Objective: Almost 90% of type 1 diabetes appears in individuals without a close family history. We sought to evaluate the best current predictive strategy, multiple defined autoantibodies, in a long-term prospective study in the general population.
Research Design And Methods: Autoantibodies to pancreatic islets (islet cell antibodies [ICAs]) and defined autoantibodies (d-aab) to human GAD, IA2/ICA512, and insulin were tested in 4,505 Washington schoolchildren. Eight years later, 3,000 (67%) subjects were recontacted, including 97% of subjects with any test >99th percentile.
Results: Six subjects developed diabetes (median interval 2.8 years), all from among the 12 individuals with multiple d-aab, representing 50% positive predictive value (95% CI 25-75%) and 100% sensitivity (58-100%). Among the others, diabetes occurred in 0 of 6 with one d-aab plus ICA, 0 of 26 with ICA only, 0 of 7 with one d-aab equaling the 99th percentile and another d-aab equaling the 97.5th percentile, 0 of 86 with one d-aab, and 0 of 2,863 with no d-aab or ICA. Adjusted for verification bias, multiple d-aab were 99.9% specific (99.86-99.93%). At this age, new d-aab seldom appeared. Once present, d-aab usually persisted regardless of disease progression, although less so for insulin autoantibodies. Insulin secretion by sequential glucose tolerance testing remained normal in four multiple d-aab subjects not developing diabetes. Of children developing diabetes, five of six (83%) would be included if HLA-DQ genotyping preceded antibody testing, but HLA-DQ did not explain outcomes among high-risk subjects, even when considered along with other genetic markers.
Conclusions: Multiple d-aab were established by age 14 years and prospectively identified all schoolchildren who developed type 1 diabetes within 8 years.
Alazwari A, Johnstone A, Tafakori L, Abdollahian M, Aleidan A, Alfuhigi K PLoS One. 2023; 18(3):e0282426.
PMID: 36857368 PMC: 9977054. DOI: 10.1371/journal.pone.0282426.
Alazwari A, Abdollahian M, Tafakori L, Johnstone A, Alshumrani R, AlHelal M PLoS One. 2022; 17(2):e0264118.
PMID: 35226685 PMC: 8884498. DOI: 10.1371/journal.pone.0264118.
A scoping review of autoantibodies as biomarkers for canine autoimmune disease.
Treeful A, Coffey E, Friedenberg S J Vet Intern Med. 2022; 36(2):363-378.
PMID: 35192227 PMC: 8965235. DOI: 10.1111/jvim.16392.
Wesley J, Pfeiffer S, Schneider D, Friedrich D, Perdue N, Sehested-Hansen B Clin Transl Immunology. 2021; 10(7):e1309.
PMID: 34267894 PMC: 8273427. DOI: 10.1002/cti2.1309.
Is It Time to Screen the General Population for Type 1 Diabetes?.
Simmons K, Michels A US Endocrinol. 2020; 11(1):10-6.
PMID: 33312232 PMC: 7731943. DOI: 10.17925/use.2015.11.1.10.